As an example, treatmentwith bevacizumab (a monoclonal antibody against VEGF) hasresulted in improved survival in colorectal cancer patients [1, 2].Other anti-angiogenic agents like angiostatin [3, 4], anti-VEGFantibody [5], receptor tyrosine kinase inhibitors [6,7, 8, 9], endostatin[10], and VEGF Trap [11] have been demonstrated to enhanceradiotherapy's effects [12, 13]. Here, VEGFA is linked to colorectal cancer.